Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
20%
Allogeneic Transplantation
20%
Bortezomib
100%
Bortezomib-based Regimen
20%
Disease Incidence
40%
Disease Rate
20%
Disease Risk
20%
Graft-versus-host Disease (GvHD)
100%
Hematopoietic Stem Cell Transplantation
100%
Human Leukocyte Antigen
60%
Immune Reconstitution
20%
Immunosuppression
100%
Improved Outcomes
20%
Incidence Rate
20%
Methotrexate
60%
Methotrexate Treatment
20%
Mortality Rate
20%
Non-relapse Mortality
20%
Overall Survival
20%
Phase II Trial
20%
Progression-free Survival
40%
Randomized Controlled Trial
20%
Randomized Phase II Trial
100%
Reduced-intensity Conditioning
100%
Sirolimus
20%
Survivors
20%
Tacrolimus
100%
Unrelated Donor
40%
Immunology and Microbiology
Acute Graft Versus Host Disease
80%
Allogeneic Hematopoietic Stem Cell Transplantation
20%
Allograft
20%
Arm
20%
Chronic Graft Versus Host Disease
20%
Conditioning
100%
Hematopoietic Stem Cell Transplantation
100%
Human Leukocyte Antigen
60%
Immune Reconstitution
20%
Immunosuppression
100%
Methotrexate
80%
Overall Survival
20%
Progression Free Survival
40%
Sirolimus
20%
Tacrolimus
100%